Stada aims for autumn IPO, reports 6% revenue growth in first half Investing.com -- German pharmaceutical company Stada is preparing for an initial public offering this fall, The Wall Street Journal reports, following a postponement earlier this year due to geopolitical uncertainty and market volatility. "We are preparing an IPO in the autumn, provided the general conditions are right," Stada Chief Executive Peter Goldschmidt said in an emailed statement to the Journal on Thursday. The private-equity backed company joins a small group of firms planning to list before year-end, after European IPO activity fell to its lowest level since early 2020 during the first half of 2025. Other companies planning listings include Thyssenkrupp’s naval division TKMS, which aims to debut on the Frankfurt Stock Exchange in mid-October, and Aumovio, a Continental AG spinoff expected to list next month. Deutsche Börse is also considering an IPO for its ISS Stoxx operations this year. Stada’s renewed IPO plans come as the company reported strong financial results for the first half of 2025. The group achieved 6% growth in adjusted constant-currency revenues, while adjusted constant-currency EBITDA improved by 5% to a record level. The company saw revenue growth across all three of its business segments: Consumer Healthcare, Generics, and Specialty. "Despite volatile market conditions, STADA achieved broad-based growth in the first half of this year, based on our diversified portfolio, strong launches and very high employee engagement rates," Goldschmidt said. The company also expanded its development portfolio with 50 new Business Development & Licensing deals signed in the first half of 2025. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Goldschmidt expressed confidence in meeting full-year guidance, noting that Stada’s "exposure to the US market, and to tariff reforms, is very limited." Several companies, including StubHub and Klarna, delayed their IPOs earlier this year amid market volatility attributed to U.S. President Trump’s tariff policies. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you invest $2,000 in CONG right now? First, check if it's included in one of this month's AI-powered stock strategies for ProPicks AI. Investing.com created these strategies to identify the most exciting trading opportunities currently in the market. The stocks that made the cut could produce monster returns in the coming years, like ViaSat and Sapiens , both up over 60%+ each in Q2 of 2025 alone. Is CONG one of them?

Click Subscribe #Stada #IPO #AutumnIPO #RevenueGrowth #StockMarket